Answers are grounded in this paper and cite their sources.
TABLEMore than 90% of new infections with the human immunodeficiency virus (HIV) occur in the developing world, where the global pandemic is still expanding in traditionally underserved populations and has an overwhelming impact on community-wide patterns of morbidity and mortality. Under such circumstances, the most important areas of HIV management concern the strategies for prevention of mother-to-child transmission and models to improve access to resources and care. The issue of research as direct development aid for many countries is contrasted with ethical questions concerning therapeutic research on populations who are unlikely to benefit from such research. The situation concerning HIV in industrialized countries is sharply different. In these countries, the research emphasis has shifted toward lessening the number of missed opportunities for prevention and to optimizing the outcome of a chronic condition in a reducing number of new patients. Similar epidemiologic differences to those listed between the developed and the developing world also exist within societies of all countries. The research issue of improving access to and compliance with care and management advice applies equally to socially disadvantaged children in the developed world. The gut is the most common portal of entry for vertically acquired postnatal HIV infection. Physiologic alterations affect gut mucosal function and the nutritional state even before the onset of frequent opportunistic infections. In the developing world, this evolving condition may be aggravated by gut damage from both undernutrition and from repeated infections due to environmental contamination, insufficient safe water and inadequate hygiene. Because gut epithelial cells do not express the CD4 receptor, HIV gains entry to the lamina propria by means of additional receptors and coreceptors. Coreceptor expression may be inducible and appears to affect susceptibility to infection. The mechanisms of mucosal infection and susceptibility remain areas of intense research. The pathogenesis of HIV enteropathy involves mucosal immune factors, lamina propria infection and inflammatory mediators. Immunomediated gut disease is associated with indicators of mucosal inflammation and damage. Malnutrition, wasting and poor growth are considered to be of multifactorial origin in HIV-infected children. Contributors include anorexia secondary to physical, pharmacological and psychosocial factors, emesis, diarrhea and alterations in metabolic rate and energy use, predominantly via increased proinflammatory cytokines. The introduction and widespread use of highly active antiretroviral therapy (HAART) has raised new concerns regarding its long-term use and side effects, as well as the differences in its availability, affordability and access. In many centers, the management of HIV/AIDS has now changed from that of treating opportunistic infections to that of managing a chronic condition. Long-term metabolic toxicities include lipodystrophy and mitochondrial damage in many different organ systems. The presence of these complications requires that interruption of antiretroviral therapy be weighed against virologic progression and the risk of development of drug resistance. Adherence to treatment schedules and compliance with medications has a number of determinants but is considered to be critical to long-term virologic success. Immune system reconstitution with a successful response to HAART is paradoxically accompanied by heightened inflammatory reactions in some instances. The scale and extent of the HIV pandemic are nothing short of overwhelming. The most effective response will require the development of new paradigms in global health care that are built on unprecedented international communication and cooperation. RESEARCH The unprecedented magnitude of the HIV/AIDS epidemic has resulted in huge research efforts and large funding opportunities at international, national, and local levels. International alliances include the United Nations Programme on AIDS (UNAIDS) as well as governmental and nongovernmental organizations and charitable foundations. Cooperative research opportunities are available on many different levels between universities, research organizations and institutes and sites in the developing world. The ethical controversies sparked by the maternal-fetal transmission trials in developing countries during the 1990s provided an impetus for revision of the Helsinki Declaration. However, it remains unresolved how to deal with absolutist ethical guidelines, which are applicable to donor countries but which may potentially prevent appropriate research into essential drugs and vaccines from taking place in developing countries, where such research might actually be welcomed as a form of direct development aid. Health Ministries should support local independent, authoritative and credible ethics committees in their own countries in their ability to decide what research is appropriate. Research Goals Improved Understanding of the Determinants of Mother-to-Child Transmission of HIV Infection A huge gap has developed between the epidemiologic patterns of childhood HIV disease applicable to the developed and the developing world. In many countries without access to the means and infrastructure to mount effective preventive and management strategies, the epidemic persists at an escalating level, and the majority of pediatric hospital admissions and deaths are now due to HIV-related complications (1). The economic and social impact of this epidemic has national and international consequences. Family and community systems are breaking down around children infected or affected by HIV through loss of caretakers and through physical, social and economic deprivation. Epidemiologic differences also apply within the societies of all countries. Social, economic and educational stratification influences the risk of infection, access to, and compliance with therapy. Even in the developed world, socially disadvantaged children have a higher risk of infection and show lesser rates of compliance with care and management advice. The most serious impediment to the introduction of cost-effective strategies for the prevention of mother-to-child transmission is a lack of the capacity and infrastructure required to provide counseling, testing, and management follow-up of all eligible women in many countries of the developing world. Prerequisites to the prevention of mother-to-child transmission are an efficient system of identification of infected women during the antenatal period by informed counseling and voluntary testing, resolution of all the issues of access, availability of therapy options and compliance and support at both the community and the healthcare system levels. In all environments, locally operative epidemiologic factors that may confer additional risk of, or indeed protection against, transmission or disease progression need to be researched in greater detail and must be documented to develop rational community-specific strategies for management and prevention. Plans to Achieve Research Goal In the developed world, the concern must be to improve identification, access and compliance in reducing numbers of patients. Multicenter studies help to maximize information gained from the study of individual patients. Research networking through scientific meetings and electronic communication must be strengthened to enable sharing of experiences, information, and even biologic materials. An instrument to follow infected children should be developed in an open, Internet-based forum and made widely available. Caregivers involved with HIV-infected children worldwide should be encouraged to enter their patients' data into the instrument every 3 to 4 months. A paid consultant should review and present the findings at 2 years and at the next international conference. In the developing world, much research effort must be trained on reducing the transmission rates to young women and their babies. Environmental factors such as intestinal parasites may influence the risk of vertical transmission by their effects on the nutritional state, gut mucosal integrity or coreceptor expression (2). Such studies should be initiated. Multicenter and multicountry cooperation supports service delivery in developing countries and maximizes research opportunities. Research is still needed to fully elucidate the role of breast milk in mother-to-child transmission in the context of societal traditions and norms, so that the impact of feeding advice and policy on community-wide patterns of infant feeding can be appreciated. In resource-limited countries with high infant mortality rates, excess deaths are usually due to gastrointestinal and respiratory infections and malnutrition. If the availability, safety and nutritional adequacy of replacement feeding cannot be guaranteed, a lowered HIV transmission rate could be cancelled out by increased morbidity and mortality from enteral infection and malnutrition in non-breast-fed infants. Improved Understanding and Management of Intestinal and Hepatic Side-Effects of Highly Active Antiretroviral Therapy The introduction of HAART has improved the outlook for children infected by HIV. Pediatric patients potentially face many decades of living with HIV/AIDS and its therapies. In view of the special requirements for childhood growth and maturation, the long-term effects and side effects of drug treatment pose particular challenges related to growth itself, metabolic toxicities, hypersensitivity reactions, compliance and virologic outcome. Poor growth is found in about 50% of HIV-infected children and is associated with the HIV RNA load, insufficient nutrient intake, and inconsistent relationships with gut abnormalities, malabsorption or neuroendocrine abnormalities. Suppression of HIV replication with HAART has a favourable effect on growth (3). Hyperlipidemia and body fat redistribution occur in 22% to 75% of adult patients exposed to HAART. This appears to be related to mitochondrial dysfunction, a direct drug effect and altered cytokine profiles. Nucleoside reverse transcriptase inhibitors cause mitochondrial dysfunction, and proteinase inhibitor drugs additionally inhibit specific enzymes in the metabolism of fat. Lipodystrophy is common and increases with duration of proteinase inhibitor use (4). At present, the long-term risks of lipodystrophy and hypercholesterolemia are unknown, as is optimal management of these conditions. Metabolic toxicities due to HAART are common and principally mediated via damage to mitochondria (5). These include presentations with anemia, myopathy, pancreatitis, neuropathy, hepatic steatosis and lactic acidosis. In addition, altered glucose metabolism and insulin resistance are seen, as are osteoporosis and osteonecrosis. The long-term effects of life-long therapy with HAART are not fully known at this stage. Apart from coping with numerous side effects, a critical element of therapy is adherence to complicated treatment schedules. Frequent regimen changes are related to virologic failure or toxicity (6). Adherence with HAART is associated with lower viral loads, and virologic failure may be related to issues of compliance. Viral suppression with HAART is followed by reconstitution of CD4 counts due to a falling viral load. Paradoxically, this may be associated with heightened inflammatory responses due to persistent immune system dysregulation, leading to atypical presentations of several coinfections (7). Research efforts are directed at possibilities of stimulating immune reconstitution in patients on HAART and counteracting injurious cytokine effects (8). Plans to Achieve Research Goal Large multicenter trials are needed to track HAART-treated children and to document the evolution of metabolic and other consequences. An Internet-based HAART utilization instrument should be established in which investigators prescribing these medications would track their efficacy and side effects. Supplemental funding should be provided so that investigators conducting therapeutic trials on HAART side effects would be encouraged to share results with other investigators, adding data to this website. Cooperative trials will be needed to delineate the best management for the complications and side effects of HAART. Improved Understanding of the Epidemiology, Pathogenesis, Pathophysiology and Management of HIV Enteropathy The gut is a common portal of entry for vertically acquired HIV infection. After crossing the gastrointestinal epithelium, HIV infects macrophages and lymphocytes in the lamina propria. Viral replication occurs in the mucosa throughout the natural history of HIV infection. In HIV infection, there is dysregulation of gut immunity (9). The immune disorder leads to both humoral and cell-mediated immune defects. Mucosal inflammation occurs with increased lamina propria mononuclear cells and increased numbers of intraepithelial lymphocytes in areas of enterocyte damage. A decrease in the CD4 cells of the lamina propria appears to be an early event. As this decline in CD4 cells continues, the histologic examination shows villous atrophy and crypt hyperplasia. This is more common in cases in which the lamina propria cells express p24 antigen. The disordered immune system itself contributes to mucosal injury, termed “HIV enteropathy” (10). Activation of T cells results in the release of various cytokines, particularly tumor necrosis factor α (TNF-α) and interferon-γ. These cytokines affect enterocyte differentiation and function. Ultrastructural studies reveal irregular, joined bases, shortened and broadened microvilli, mitochondrial swelling, formation of lysosomal and vesicular bodies and dilated endoplasmic reticulum, as well as tubuloreticular inclusions in the endothelial cells (11). Further studies are needed to elucidate the precise pathogenesis of intestinal injury and possible methods of management. Initially, the ongoing immune response to HIV infection results in disease; later, this is due to opportunistic infection. Adult studies suggest that the earliest stage is characterized by delayed hypersensitivity phenomena. In the intermediate stage, there is generalized activation of all classes of cytokines. In the late stage of HIV infection, there is predominant activation of the proinflammatory cytokines TNF-α and interleukin-1β. These immune reactions are likely directed at HIV, but some features are similar to graft-versus-host disease and may include autoimmune processes. Some studies did not support the role of inflammatory mediators and CD4 T-cell activation in the pathogenesis of HIV enteropathy (12). Thus, the relative role and importance of direct HIV-mediated effects or cytokine-mediated mucosal changes has yet to be clearly elucidated. The mucosal inflammation is accompanied by disproportionately severe functional disturbance. As a result, the patients develop diarrhea, malnutrition, growth retardation and immune dysfunction. The pathogenesis of the wasting syndrome in patients with HIV infection is most likely to be multifactorial. Possible contributing factors are insufficient intake due to anorexia, vomiting, psychosocial factors, malabsorption, increased energy requirements and increased circulating cytokines such as TNF-α, interleukin-1 or interleukin-6. Derangements in lipid cycling and metabolism compromise the growth of HIV-infected children in between opportunistic infections. Because of immune function secondary to malnutrition is potentially nutritional in HIV-infected children may have a effect on immune lower cytokine decrease opportunistic infection and HIV replication The role of nutritional to be in to its effect on immune and outcome. gut can be by several and as well as by altered release of gastrointestinal and dysfunction. In adult has to occur early in the In the late stage of HIV infection, gastrointestinal disease is most due to opportunistic and infection. The of is as in but are more associated with chronic of infected factors and to potentially and but at the to The role of in nutritional management of HIV-infected children still to be Plans to Achieve Research Goal to a of HIV should be and specific infections The results of these as well as other data should be into an developed and with appropriate A consultant should be for these data and to the natural of HIV enteropathy in 2 years and at the next international Multicenter studies should be to the evolution and management of enteropathy from gut are needed in the developing world to the relative importance of the to HIV in breast milk in the rate of progression of disease and nutritional to biologic and research such as with specific cytokines or or will enable greater scientific to be of and should also be via the to a evolution of HIV The with the impact include those that concern on prevention and care and Goals Improved to and of to Because antiretroviral drugs are not a access to HIV care to be to prevention will in provide new opportunities for it will a and infrastructure for HIV testing, new entry to the healthcare system for those who are critical opportunities to support their and to prevent ongoing and with and social should be to access care in an for voluntary counseling and testing, for health and social and for support and care challenges for healthcare systems include and human and of and use of Plans to Achieve Goal must be of secondary and care in different and at different with special in treating and children with HIV infection can be to care and community service The should have and a of and to community In to and must be made available in health and antenatal to women and their women should be management and follow-up support in with the best available applicable to that particular or who have and in areas with high should be to women from their to in the women can be the of replacement feeding in developing countries, a of or must be However, the of infant feeding advice to HIV-infected must be particularly to individual context and the of the is this should be fully and Improved and of related to and of antiretroviral drugs out of of most children in developing countries. Even in the context of healthcare systems in the developed world, there are challenges in improving access to antiretroviral drugs The healthcare a role in treatment and and other effective resources and Plans to Achieve Goal should be encouraged to a health to the of antiretroviral drug use in resource-limited access to for living with HIV/AIDS must be an established of all access can be improved not by on the rational and use of antiretroviral drugs but also by improved affordability and of drug and by appropriate and healthcare The medications must be made available. The of regarding side effects and should be by an on an The should be in drug of increased from an increased role for international regarding and the of charitable to provide additional should be developed to and through the of these strategies include of at which could of a system to track the of and of a of for should be by Internet-based so that in this as well as effects of can be The Health should be with in of the of on and Management of HIV Enteropathy In the developing world, the evolving gut condition of HIV enteropathy is on and aggravated by a high of and nutritional gut Under such circumstances, a cost-effective is needed for the and management of HIV-infected children with chronic or persistent diarrhea or nutritional Plans to Achieve Goal A must to cost-effective treatment of children with gut disease and to prevent nutritional as as The nutritional management of patients with enteropathy and to and to maximize and The energy is increased to of available and methods of should be where possible to and Goals Improved and to on of Mother-to-Child Transmission Because prevention of infection in the is the it is on all healthcare involved in the of HIV-infected women at antenatal to be informed about all of mother-to-child transmission during the period and through The is to the viral during the of and during to to a during and and to provide therapy as for the who might have infected during Plans to Achieve Goal In countries, the of all in the and healthcare must be in This should be by a to management and must be to and affected patients that will the community-wide and of Improved on Management challenges will require the healthcare to its and to new with the with and infected and affected with HIV, and with the models of with the community are particularly important to with Ministries of Health and to improve the and of health Plans to Achieve Goal An international of should be established to support the development and of that provide information and for healthcare to in developing countries should be with national to to improve treatment for children living with HIV include of health and other Research on improved treatment to include Internet-based sharing of information about so that can be to In this for and will be made available for healthcare in and are important of and require the of and to educational The of patients who have to and to therapy may have a impact on community by role but must be with of individual and societal and Antiretroviral treatment should be developed and should a and a number of for use, that who cannot or who the and would be for care by should be on the best scientific to the use of treatment that compromise the outcome of treatment in individual and the for the of Improved and in of and wasting are the most chronic and to HIV-infected children. A poor nutritional state and wasting are associated with a and an improved nutritional state and growth may from effective viral suppression with HAART. successful nutritional may improve function. and have an important role in and in the outcome of HIV-infected children. are but may have effects. Plans to Achieve Goal should include a greater emphasis on nutritional care. This should be at and service should be to provide specific and these should be on the nutritional is most effective in the early of disease and should be provided in with management of other associated but nutritional should be the to growth The is to the and to maximize energy by the of fat or is the this should be as the as as possible and the own and state of health as as HIV-infected children with diarrhea require in to nutritional of and are many opportunities for and and in childhood HIV The of funding for this from and is The that now the healthcare is to a role in the available resources to have a impact on the number of infected
No takes yet. Share an insight, caveat, or question.
Wittenberg et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: